Iomai (IOMI) Reports a Full-Year Loss
More News related to IOMI
- Unusual 11 Mid-Day Movers 5/13: IOMI, CSIQ, FSYS, WCI, USNA Higher; NXTM, USS, CRZ, IMB Lower
- Pre-Open Movers 5/13: Canadian Solar (CSIQ) Jumps On Strong Results; Pilgrims Pride (PPC) Lower on Offering
- Intercell AG To Acquire Iomai (IOMI) for $6.60/Share
- Iomai (IOMI) Reports a Full-Year Loss
- StreetInsider.com Pre-Open Movers 09/19
More News related to Earnings
- Top 10 News Items 11/23-11/27: Dubai Debt Fallout; Gold; GDP Revised Lower; Diedrich Coffee Bidding War
- Trading Radar for 11/30: Inergy Holdings (NRGP), Golar (GLNG), Omnivision (OVTI), Knightsbridge (VLCCF) Report
- Notable Mergers and Acquisitions of the Day for 11/27: F, S/IPCS, STAR/CSCO, HRAY
- Notable Analyst Rating Changes 11/27: TIF, QLTI Upgraded; FSNM, RGFC Downgraded
- Notable ETF Movers *Special Dubai World Edition* 11/27: UUP Higher; GAF, EEM, FXI, XLF Lower
Iomai Corporation (Nasdaq: IOMI) reports a FY07 loss of $1.16, 4 cents better than estimates. Revenues were $10.67 million vs. $10.92 million consensus.
Iomai Corporation is a biopharmaceutical company focused on the discovery, development and commercialization of vaccines and immune system stimulants delivered to the skin via a needle-free technology called transcutaneous immunization (TCI). [SM]
Related Categories
EarningsStocks Mentioned
+0.00Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
